Viewing Study NCT03120195


Ignite Creation Date: 2025-12-24 @ 1:57 PM
Ignite Modification Date: 2026-02-25 @ 7:21 PM
Study NCT ID: NCT03120195
Status: COMPLETED
Last Update Posted: 2020-01-29
First Post: 2017-04-04
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: EndoRotor® Ablation of Barrett's Esophagus: Safety and Feasibility Study
Sponsor: Foundation for Liver Research
Organization:

Study Overview

Official Title: EndoRotor® Ablation of Barrett's Esophagus: Safety and Feasibility Study
Status: COMPLETED
Status Verified Date: 2020-01
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The aim of this study is to assess the safety and feasibility of the EndoRotor® for the ablation of Barrett's esophagus.
Detailed Description: Prospective pilot study, to be performed in 30 patients with Barrett's esophagus that have an indication for ablation treatment. These include patients with low grade dysplasia (LGD), high grade dysplasia (HGD) or residual Barrett's after a complete endoscopic resection of a lesion containing HGD or esophageal adenocarcinoma. Ablation treatment will be performed by the EndoRotor ablation device, followed by surveillance endoscopy at 3 months where the feasibility for ablation will be assessed. During the 3 months follow-up, all adverse events such as perforation, post-procedural bleeding, stricture, and pain will be registered.

The EndoRotor® System is in automated mechanical endoscopic mucosal resection system for use in the gastrointestinal tract. The EndoRotor suctions up the tissue and cuts it, automatically sending the tissue to a collection trap for histological evaluation.

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: